{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:09:05Z","timestamp":1781258945524,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate efficacy and safety of filgotinib in Japanese RA patients who have failed or were intolerant to one or more biologic disease-modifying antirheumatic drugs (bDMARD) from the global FINCH 2 study (NCT02873936)<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This subgroup analysis was performed using the predefined statistical analyses. The FINCH 2 study is a randomized, double-blind, placebo-controlled, Phase 3 study in adult RA patients with inadequate response to bDMARDs. The randomized patients were treated with once-daily filgotinib 200\u2009mg, filgotinib 100\u2009mg or placebo on a background of csDMARDs for 24 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 449 patients enrolled in the overall population, 40 patients were enrolled from Japan. In the Japanese population, the American College of Rheumatology 20% response rates at week 12 (primary endpoint) were 83.3% and 53.3% for filgotinib, 200\u2009mg and 100\u2009mg, respectively, vs 30.8% for placebo. Filgotinib was well tolerated, similar to the overall population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Both doses of once-daily filgotinib 200\u2009mg and filgotinib 100\u2009mg were effective, and generally well-tolerated in Japanese patients with active refractory RA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1080\/14397595.2020.1859675","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T12:10:00Z","timestamp":1607083800000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2)"],"prefix":"10.1093","volume":"32","author":[{"given":"Tsutomu","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Matsubara Mayflower Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Aichi Developmental Disability Center, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Genovese","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kalunian","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Walker","sequence":"additional","affiliation":[{"name":"Northumbria Healthcare, North Shields, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Bartok","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Pechonkina","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kondo","sequence":"additional","affiliation":[{"name":"Gilead Sciences K.K, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Tasset","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S","family":"Sundy","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"issue":"9285","key":"2022010903470106300_R1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"issue":"25","key":"2022010903470106300_R2","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMra040226","article-title":"Therapeutic strategies for rheumatoid arthritis","volume":"350","author":"O\u2019Dell","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"2022010903470106300_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022010903470106300_R4","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022010903470106300_R5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.10.003","article-title":"Treatment of rheumatoid arthritis: unraveling the conundrum","volume":"65","author":"Zampeli","year":"2015","journal-title":"J Autoimmun"},{"issue":"1","key":"2022010903470106300_R6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"issue":"5","key":"2022010903470106300_R7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"5-6","key":"2022010903470106300_R8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1759720X18776224","article-title":"The role of the JAK\/STAT signal pathway in rheumatoid arthritis","volume":"10","author":"Malemud","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"Suppl 1","key":"2022010903470106300_R9","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","author":"Westhovens","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2022010903470106300_R10","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J Immunol"},{"issue":"6","key":"2022010903470106300_R11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2022010903470106300_R12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2022010903470106300_R13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"2022010903470106300_R14","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2022010903470106300_R15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2022010903470106300_R16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2022010903470106300_R17","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"issue":"2","key":"2022010903470106300_R18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2022010903470106300_R19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2022010903470106300_R20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"5 Suppl 39","key":"2022010903470106300_R21","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"2022010903470106300_R22","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2022010903470106300_R23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2022010903470106300_R24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrrheum.2010.154","article-title":"The Japanese experience with biologic therapies for rheumatoid arthritis","volume":"6","author":"Takeuchi","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"2022010903470106300_R25","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022010903470106300_R26","doi-asserted-by":"crossref","DOI":"10.1080\/25785826.2020.1770948","article-title":"JAK inhibitors for the treatment of rheumatoid arthritis","author":"Morinobu","year":"2020","journal-title":"Immunol Med"},{"issue":"11","key":"2022010903470106300_R27","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1136\/ard.2011.154179","article-title":"Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire","volume":"70","author":"Haraoui","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2022010903470106300_R28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/14397595.2018.1551274","article-title":"Age and quality of life in patients with rheumatoid arthritis treated with biologic agents","volume":"30","author":"Oguro","year":"2020","journal-title":"Mod Rheumatol"},{"issue":"12","key":"2022010903470106300_R29","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1002\/art.11358","article-title":"Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade","volume":"48","author":"Redlich","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2022010903470106300_R30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14397595.2019.1589918","article-title":"Radiographic and clinical outcomes following etanercept monotherapy in Japanese methotrexate-na\u00efve patients with active rheumatoid arthritis","volume":"30","author":"Takeuchi","year":"2020","journal-title":"Mod Rheumatol"},{"issue":"4","key":"2022010903470106300_R31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"Biodrugs"},{"issue":"1","key":"2022010903470106300_R32","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar3249","article-title":"Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-\u03b1 inhibitors","volume":"13","author":"Rendas-Baum","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2022010903470106300_R33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2022010903470106300_R34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/14397595.2017.1392057","article-title":"Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1080\/14397595.2020.1859675\/41818257\/1859675.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/59\/42083579\/1859675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/59\/42083579\/1859675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:55:42Z","timestamp":1642560942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/1\/59-67\/6469667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,18]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1080\/14397595.2020.1859675","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,1,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}